Graduation Date

Spring 5-7-2026

Document Type

Dissertation

Degree Name

Doctor of Philosophy (PhD)

Programs

Pharmaceutical Sciences

First Advisor

Dr. Corey Hopkins

Abstract

Alzheimer’s disease (AD), Parkinson’s disease (PD), and colorectal cancer (CRC) remain significant clinical challenges requiring improved therapeutic strategies. This dissertation describes the design, synthesis, and pharmacological evaluation of structurally diverse small-molecule scaffolds targeting the sigma-1 receptor (S1R) for symptomatic modulation in AD, the dopamine D4 receptor (D4R) for management of L-DOPA–induced dyskinesia in PD, and claudin-1 for targeted intervention in CRC. Fused azabicyclic scaffolds were developed as S1R modulators, and systematic structure–activity relationship (SAR) studies identified key structural features governing receptor affinity, selectivity, metabolic stability, and central nervous system penetration. Optimized analogs demonstrated improved metabolic stability and favorable brain exposure, supporting their potential as CNS-active agents. Spirocyclic azabicyclic scaffolds were investigated to modulate D4R affinity and selectivity. SAR analyses revealed that incorporation of spirocyclic frameworks maintains D4R affinity while maintaining acceptable pharmacokinetic properties. Finally, optimization of claudin-1 inhibitors identified structural features critical for potency and metabolic stability, advancing the development of small-molecule inhibitors targeting tight junction dysregulation in CRC. Collectively, this work establishes strategic medicinal chemistry approaches for tuning receptor affinity, selectivity, and pharmacokinetic properties to support the development of small-molecule therapeutics for neurodegenerative diseases and oncology.

Rights

The author holds the copyright to this work and any reuse or permissions must be obtained from the author directly.

Available for download on Saturday, October 10, 2026

Share

COinS